Login to Your Account



Crucell Acquires SBL Vaccin For €40M Cash, Raises €80M

By Cormac Sheridan


Wednesday, November 29, 2006

Bolstering its position in the travel vaccines market, as well as its cash balance, Crucell NV completed the acquisition of SBL Vaccin AB for €39.4 million (US$51.9 million) cash and raised €80 million through a new share issue. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription